Innovent Biologics Inc (STU:6IB) Stock News, Headlines & Updates
Innovent Biologics Inc Stock News from GuruFocus
- 1
Aug 22, 2024
China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
PRNewswire • 8:00pm
Aug 02, 2024
Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)
PRNewswire • 8:00pm
Aug 01, 2024
Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China
PRNewswire • 4:00am
Jul 26, 2024
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
PRNewswire • 9:00pm
Jul 22, 2024
Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
PRNewswire • 8:00pm
Jul 08, 2024
Innovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate Responsibility
PRNewswire • 8:00pm
Jul 05, 2024
Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
PRNewswire • 4:00am
Jun 28, 2024
Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline
PRNewswire • 8:00pm
Jun 25, 2024
Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024
PRNewswire • 8:00pm
Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions
PRNewswire • 8:00pm
Jun 19, 2024
Innovent Reports Oncology Pipeline Updates at Investor Meeting
PRNewswire • 10:00pm
Jun 13, 2024
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
PRNewswire • 8:00pm
Jun 12, 2024
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
PRNewswire • 8:00pm
Jun 02, 2024
Innovent Announces Taletrectinib?ROS1 Inhibitor?Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
PRNewswire • 1:00am
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2? Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
PRNewswire • 8:00pm
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib?ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
PRNewswire • 8:00pm
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
PRNewswire • 8:00pm
May 28, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news